tirzepatide cvot trial π‘ New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT found that was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What New SURPASS-CVOT Ad Hoc Analysis:
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 8 - Aug 13









.jpg?RenditionID=6)












